Jay R. Luly Enanta Pharmaceuticals Inc (ENTA) insider trading activity

Jay R. Luly is President and CEO of ENANTA PHARMACEUTICALS INC. Currently has a direct ownership of 810,609 shares of ENTA, which is worth approximately $7.3 Million. The most recent transaction as insider was on Feb 12, 2024, when has been sold 1,584 shares (Common Stock) at a price of $12.41 per share, resulting in proceeds of $19,657. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 811K

0% 3M change

1.12% 12M change

Total Value Held $7.3 Million

Jay R. Luly Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 12 2024	SELL Payment of exercise price or tax liability	$19,657 $12.41 p/Share	1,584 Reduced 0.2%	810,609 Common Stock
Feb 12 2024	BUY Grant, award, or other acquisition	-	5,400 Added 0.66%	812,193 Common Stock
Dec 05 2023	SELL Open market or private sale	$69,624 $9.63 p/Share	7,230 Reduced 0.89%	806,793 Common Stock
Dec 01 2023	SELL Payment of exercise price or tax liability	$54,918 $9.49 p/Share	5,787 Reduced 0.71%	814,023 Common Stock
Mar 13 2023	SELL Open market or private sale	$1,267,763 $45.42 p/Share	27,912 Reduced 3.29%	819,810 Common Stock
Mar 13 2023	BUY Exercise of conversion of derivative security	$390,768 $14.0 p/Share	27,912 Added 3.19%	847,722 Common Stock
Feb 13 2023	SELL Payment of exercise price or tax liability	$1,086,587 $52.77 p/Share	20,591 Reduced 2.51%	799,219 Common Stock
Feb 13 2023	BUY Grant, award, or other acquisition	-	31,505 Added 3.7%	819,810 Common Stock
Dec 19 2022	BUY Exercise of conversion of derivative security	$399,910 $27.58 p/Share	14,500 Added 1.81%	788,305 Common Stock
Dec 16 2022	SELL Open market or private sale	$1,336,200 $44.54 p/Share	30,000 Reduced 3.73%	773,805 Common Stock
Dec 16 2022	BUY Exercise of conversion of derivative security	$422,700 $14.09 p/Share	30,000 Added 3.6%	803,805 Common Stock
Dec 01 2022	SELL Payment of exercise price or tax liability	$250,863 $44.33 p/Share	5,659 Reduced 0.73%	773,805 Common Stock
Nov 23 2022	BUY Grant, award, or other acquisition	-	63,000 Added 7.48%	779,464 Common Stock
Feb 14 2022	SELL Payment of exercise price or tax liability	$147,164 $62.49 p/Share	2,355 Reduced 0.33%	716,464 Common Stock
Feb 14 2022	BUY Grant, award, or other acquisition	-	8,028 Added 1.1%	718,819 Common Stock
Jan 15 2022	BUY Exercise of conversion of derivative security	$118,442 $11.77 p/Share	10,063 Added 1.4%	710,791 Common Stock
Dec 01 2021	SELL Payment of exercise price or tax liability	$170,450 $87.68 p/Share	1,944 Reduced 0.28%	700,728 Common Stock
Nov 19 2021	BUY Grant, award, or other acquisition	-	25,700 Added 3.53%	702,672 Common Stock
Sep 15 2021	SELL Open market or private sale	$266,715 $59.06 p/Share	4,516 Reduced 0.66%	676,972 Common Stock
Dec 15 2020	SELL Payment of exercise price or tax liability	$93,587 $42.52 p/Share	2,201 Reduced 0.32%	681,488 Common Stock
Dec 15 2020	BUY Exercise of conversion of derivative security	-	7,500 Added 1.09%	683,689 Common Stock
Nov 20 2020	BUY Grant, award, or other acquisition	-	26,500 Added 3.77%	676,189 Common Stock

JRL

Jay R. Luly

President and CEO

Watertown, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ENTA shares.

Notify only if

Value

Insider Trading

Get notified when an Enanta Pharmaceuticals Inc insider buys or sells ENTA shares.

Notify only if

Operation

Value

Type

News

Receive news related to ENANTA PHARMACEUTICALS INC

Track Activities on ENTA

Account